Methods. We have studied in peripheral blood (PB) and synovial fluid (SF ) of 31 patients diagnosed with rheumatoid arthritis (RA), the expression of CD5 and CD23 antigens on B cells, and the levels of soluble CD23 (sCD23), interleukin-4 (IL-4) and tumour necrosis factor alpha (TNF-a). We have also correlated the results with the disease activity index.
The origin and function of CD5+ B cells are controver-B lymphocytes, T cells, monocytes and eosinophils [16 ] . sial [1, 2] . The description in rheumatoid arthritis (RA) In B cells, the expression of CD23 in cellular membrane patients of an expansion in peripheral blood (PB) of (mCD23) might regulate the main functions of B cells: CD5+ B cells [3] and the production by these cells of antigen presentation to T cells and their differentiation autoantibodies of rheumatoid factor type [4] had implito immunoglobulin-secreting cells [17] . The soluble cated this cellular population in the disease's pathogenform, sCD23, is a multifunctional cytokine that might esis [5] . The studies carried out in PB of RA patients participate in the inflammatory process and in the reveal contradictory results: some demonstrate expanmechanisms of apoptosis [18, 19] . The expression and sion of the CD5+ B-cell population compared to normal release of CD23 are upregulated by interleukin-4 (IL-4) controls and correlation with disease activity [3, 4, [6] [7] [8] , [20, 21] , and downregulated by interferon c [22] . Several others do not find a correlation with disease activity but authors have described increased expression of mCD23 expansion in PB [9, 10] and, finally, other studies do on B lymphocytes and increased levels of sCD23 in RA not find differences with normal controls [11] [12] [13] [14] . This patients [23] [24] [25] [26] . It has been suggested that the increased discrepancy in the results could be explained by the idea serum levels of sCD23 in RA patients are due to a high that CD5+ B cells levels are genetically regulated, so expression of mCD23 on CD5+ B cells [27] . that some patients would have normal levels and others
The majority of studies on the expression of CD5 and elevated levels of CD5+ B cells [15] .
CD23 antigens on B cells of RA patients have been CD23 antigen (the low-affinity receptor for IgE ) is a performed in PB; the studies in synovial fluid (SF ) are membrane protein present in several cell types such as scanty and have a low number of patients. The aim of this work was to study, in PB and SF of RA patients, the CD5+ B-cell population and the ( TNF-a), and correlate the results with the activity of In total B cells, the expression of mCD23 was higher the disease.
in PB than in SF (P < 0.001). On CD5+ and CD5− B cells, the expression of mCD23 was similar in PB; in both cases, mCD23 expression was higher in PB than
Patients and methods in SF, but only with a significant difference on CD5− Thirty-one patients diagnosed with RA according to the B cells (P < 0.001). CD5+ B cells expressed higher 1987 American College of Rheumatology (formerly levels of mCD23 in SF than CD5− B cells (P < 0.05). American Rheumatism Association) revised criteria [28] Data are shown in Table 1 . were studied. Once informed consent was obtained,
The levels of IL-4 and sCD23 were determined in paired samples of PB and SF were obtained by venous paired samples of plasma and SF of 28 patients, and puncture and by aseptic aspiration of the knee joint, the levels of TNF-a in 12. Twelve patients had detectable respectively. The disease activity was measured using levels of IL-4 (>3 pg/ml ) in plasma and 10 in SF the modified Stoke index [29] . The Stoke index is an (nine in both samples); there were no differences algorithm scoring inflammatory activity that includes between plasma and SF levels (28.37 ± 12.56 vs clinical (proximal interphalangeal score, morning stiff-13.85 ± 4.57 pg/ml; P = 0.34). sCD23 was detected in ness, Ritchie articular index) and biological data (erythall cases, the amount in plasma was slightly higher than rocyte sedimentation rate, C-reactive protein). The result that in SF (2.88 ± 0.41 vs 2.55 ± 0.29 mg/l; P = 0.21). is an index score ranging from 1 (minimal activity) to
The concentration of TNF-a was higher in SF than in 17 (maximum activity). The modification introduced by plasma (2479 ± 574 vs 44.2 ± 9.2 pg/ml; P < 0.
001). us was to use the Thompson articular index [30] instead
We have found a significant negative correlation of the Ritchie articular index; the final score index was between TNF-a and sCD23 levels in SF (r = −0.555, unchanged. The mean age (± ...) of the patients was P < 0.05); there was no correlation between plasma 62.2 (± 2.2) yr, five patients were males and 26 females.
levels. IL-4 levels were not detectable either in plasma Twenty-five patients had rheumatoid factor in their sera.
or in SF in the 12 cases in which TNF-a was determined. The mean duration of the disease was 7.1 (± 1.5) yr, Patients were divided into two groups: one with and the mean activity index 8.6 (± 0.7).
detectable levels of IL-4 both in plasma and SF, and Owing to the impossibility of obtaining inflammatory the other with no detectable levels in either sample. SF from normal subjects, and because the aim of the There were no significant differences in the expression study was to compare the results in PB and SF of RA of CD5 on B cells between groups, either in PB patients, we have not included normal controls in this (27.7 ± 4.3% vs 25.1 ± 3.9%; P = 0.65) or in SF work.
(42.8 ± 6.2% vs 42 ± 5.6%; P = 0.93). On CD5+ B Mononuclear cells were isolated either from venous cells, mCD23 expression was lower in the group with blood or from SF samples by Ficoll-Hypaque densitydetectable IL-4 levels, both in PB (12 ± 5.8% vs gradient centrifugation. Plasma and cell-free SF 31.3 ± 7.4%; P = 0.008) and in SF (8.1 ± 5.1% vs obtained by centrifugation were kept at −80°C until 17.2 ± 5.6%; P = 0.16) ( Fig. 1) . Conversely, on CD5− studied.
B cells, mCD23 expression was higher in the IL-4 A three-colour labelling procedure was performed to detectable group, both in PB (25.8 ± 3.8% vs assess B-cell phenotype. Anti-CD20 Per-CP, anti-CD5 17.8 ± 3.1%; P = 0.13) and in SF (9.1 ± 3.4% vs fluorescein isothiocyanate ( FITC ) and anti-CD23 phy-2 ± 0.6%; P = 0.07). As occurred with mCD23 exprescoerythrin (PE) monoclonal antibodies from Becton sion on CD5+ B cells, sCD23 levels were lower in the Dickinson were used. After a standard labelling proced-IL-4 detectable group, both in plasma (1.98 ± 0.13 vs ure, cells were analysed in a FacSort cytometer (Becton 3.56 ± 0.68 mg/l; P < 0.01) and in SF (2.12 ± 0.67 vs Dickinson).
2.79 ± 0.27 mg/l; P < 0.05). Soluble CD23 was quantified in plasma and SF by a
We have not found any significant correlation between 'sandwich' enzyme immunoassay ( The Binding Site, the disease activity index and the different parameters Birmingham, UK ), the limit of detection was 0.7 mg/l. studied (percentage of CD5+ B cells, mCD23 expresLevels of IL-4 and TNF-a were measured in plasma sion on CD5+ and CD5− B cells, and sCD23, IL-4 and SF samples by ELISA ( Endogen, Cambridge, MA, and TNF-a levels) either in plasma/PB or in SF (data USA) following the manufacturer's instructions. The not shown). limit of detection was 3 and 4 pg/ml, respectively.
Results are given as mean ± ... The two-tailed t-test, the non-parametric Mann-Whitney test and The percentage of CD5+ B cells was significantly higher
Data express percentages (mean ± ...).
in SF (41.8 ± 3.8%) than in PB (25.7 ± 2.6%)
aCD5+ B cells express more mCD23 in SF than CD5 − B cells (P < 0.05).
have seen that mCD23 expression on CD5+ B cells was higher in the absence of IL-4 (although only with a significant difference in PB); this finding might indicate a different functional behaviour of CD5+ B cells with respect to IL-4. As occurred with mCD23 expression on CD5+ B cells, sCD23 levels were higher in the absence of IL-4; this might indicate, as has been suggested by Ikizawa et al. [27] , that CD5+ B cells expressing mCD23 are the main source of sCD23 in RA patients. The lower expression of mCD23 on CD5+ B cells and the lower amounts of sCD23 in the presence of IL-4 suggest that this is due to a decrease in production and not to an increased shedding of the molecule.
The capacity of human CD23 to activate monocytes/ macrophages by binding to the b2 integrins CD11b and CD11c, producing the release of pro-inflammatory mediators such as TNF-a, IL-1b and IL-6, has been described logical progression of an established arthritis [38] . We have found a negative correlation in SF of RA patients between TNF-a and sCD23 levels; the meaning of this Discussion finding, if any, needs further investigation.
To the best of our knowledge, the study described In the present report, we describe an expansion of CD5+ B cells in SF of RA patients. This may be due here is the largest yet performed on SF of RA patients regarding the expression of CD5 and CD23 molecules to active traffic to SF of this cellular subtype or to an increase in local production of the CD5 molecule in this on B cells. The CD5+ B cells are increased in SF of RA patients and show a higher expression of mCD23 environment. There are few studies comparing the CD5+ B-cell population in PB and SF of RA patients.
than CD5− B cells. The absence of IL-4 is related to a higher expression of mCD23 on CD5+ B cells, and Sowden et al. [11] analysed in six RA patients the expression of CD5 on B cells of PB and SF and, as in with higher levels of sCD23. There is a negative correlation in SF between TNF-a and sCD23 levels. There is our study, they found a higher proportion of CD5+ B cells in SF. Kipps [1] , in his comprehensive review of no correlation between the disease activity index and the different parameters studied (CD5 and CD23 expresthe CD5+ B cell, makes mention of an increase of CD5+ B cells in SF of RA patients without offering sion on B cells, and IL-4, sCD23 and TNF-a levels) either in plasma/PB or in SF. concise data.
Fernández-Gutiérrez et al. [25] have studied the expression of mCD23 on B cells of RA patients (24
